Affinity determination is the process of quantifying how strongly two molecules bind to each other—commonly protein–protein, antibody–antigen, receptor–ligand, or protein–small molecule interactions. In most bioscience and drug discovery contexts, affinity is summarized by the equilibrium dissociation constant (KD):
Lower KD = higher affinity (tighter binding).
KD is an equilibrium quantity, meaning it reflects the balance between binding and unbinding at steady state.
A related way to express the same concept is the association constant (KA), where KA = 1 / KD.
Affinity can be described in two complementary ways:
KD (M): concentration at which half of binding sites are occupied in a simple 1:1 interaction model.
KA (M⁻¹): binding strength as an association constant (inverse of KD).
Many instruments determine affinity by measuring rates:
kon (M⁻¹·s⁻¹): association/on-rate (how quickly complex forms)
koff (s⁻¹): dissociation/off-rate (how quickly complex falls apart)
For a 1:1 interaction:
KD = koff / kon (at equilibrium). Surface-based biosensors often estimate affinity by extracting these rates from real-time binding curves.
Affinity is not just a bragging-rights number. It influences:
Dose requirements (tighter binding can enable lower effective concentrations)
Specificity and selectivity (high affinity can help, but does not guarantee specificity)
Residence time (often tied to koff; slow off-rate can matter in pharmacology)
Comparability across candidates (rank-ordering binders in discovery pipelines)
Different methods trade off realism, throughput, equipment needs, and what they measure (equilibrium vs kinetics).
SPR measures binding in real time by detecting refractive index changes near a sensor surface. It is widely used for extracting kon, koff, and KD from sensorgrams (binding curves). Key ideas include reference subtraction, controlling immobilization, and fitting to binding models (often starting with a 1:1 Langmuir model).
Strengths
Provides kinetics (kon/koff) and affinity (KD) in a single workflow
Label-free detection
Common pitfalls
Mass transport limitations (apparent kinetics distorted by diffusion limits)
Surface immobilization artifacts (orientation, density, steric hindrance)
Non-specific binding and baseline drift that complicate fitting
ITC measures heat released/absorbed during binding in solution. From titration curves, it can yield:
KA (or KD)
ΔH (enthalpy)
ΔS (entropy)
n (stoichiometry)
This is powerful because it connects “how strong” with “why strong” (enthalpy-driven vs entropy-driven binding).
Strengths
Fully solution-based, label-free
Rich thermodynamic interpretation
Common pitfalls
Requires sufficient heat signal and careful concentration design
Extremely tight binding can require special designs (e.g., displacement approaches)
Competition ELISA can estimate binding strength by letting soluble analyte compete with immobilized antigen (or vice versa). Under proper conditions, it can approximate true solution affinity without specialized instrumentation, and is often used when SPR/ITC is unavailable.
Strengths
Lower barrier to entry (standard immunoassay equipment)
Useful for comparative ranking when carefully designed
Common pitfalls
Assay conditions must preserve equilibrium assumptions
Immobilization and avidity (multivalency) can skew apparent affinity
IC50-to-KD relationships require correct regime and modeling
A frequent source of confusion in affinity determination is apparent affinity—a value that looks like KD but actually reflects additional effects:
Avidity (multivalent interactions can appear tighter than single-site binding)
Heterogeneous binding sites (mixed populations produce non-1:1 behavior)
Surface artifacts (for SPR/ELISA formats)
A robust affinity workflow typically includes:
Testing multiple concentrations
Checking residuals and model fit quality
Running controls for non-specific binding
Evaluating whether a simple 1:1 model is justified
If you need kon/koff + KD and can work with surfaces: SPR
If you need thermodynamics (ΔH/ΔS) + stoichiometry in solution: ITC
If you need accessible, instrument-light comparisons: competition ELISA
In practice, teams often combine methods: for example, SPR for kinetic ranking plus ITC on finalists for mechanistic confidence.
Screening of aptamers and their potential application in targeted diagnosis and therapy of liver cancer
Aptamer Screening- Current Methods and Future Trend towards Non-SELEX Approach
Aptamer Discovery Platform
Aptamer Screening Services for Peptide
selexkmdbio-Cell Nucleic Acid Aptamer Screening Service
Current Status and Future Directions of Aptamer Development
Major Application Fields of Aptamers
Key Characteristics and Working Principle of Aptamers
aptamer
Aptamer screening via SELEX for molecular recognition
APTAMER SCREENING METHODS
Aptamer screening technologies
Toggle-SELEX Aptamer Screening Service
Negative Aptamer Selection- A Practical Guide to Improving Aptamer Specificity in SELEX
selexkmdbio-Cell Nucleic Acid Aptamer Screening Service
Aptamer Screening- Current Methods and Future Trend towards Non-SELEX Approach
Aptamer Screening Service-Subtractive SELEX
Aptamer Screening Service-Counter SELEX
Aptamer Screening Service-HT-SELEX
Aptamer Screening Service-NGS-SELEX
Aptamer Screening Service-Multi-Round SELEX Screening
Whole Cell-SELEX Aptamer Screening Service
Membrane Protein Aptamer Screening Service
Aptamer Screening Service for Drug Discovery
Aptamer Live Cell SELEX Service
Classical SELEX Service for Aptamer
Aptamer Selection and Identification
Aptamer Screening Process and Applications Overview